Verve Therapeutics
VERV
Performance
About Verve Therapeutics
Verve Therapeutics is a biotechnology company focused on developing genetic medicines to prevent cardiovascular disease. The company emphasizes gene editing approaches, delivery systems, and genetic targets to treat cardiovascular conditions, aiming to address the global burden of ASCVD. Its pipeline includes programs such as VERVE-102 and VERVE-201, reflecting a focus on in vivo genetic interventions for cardiovascular disease. Verve Therapeutics operates in the field of cardiovascular biotech, pursuing therapies that could reduce disease risk and improve outcomes worldwide.
Recent News
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
Weekly Reads: Effective LDL Gene Editing, Chinese Genetics Guidelines, Human Embryo Models in Space
STAT+: Pharmalittle: We’re Reading About a Lilly Gene Therapy for Cholesterol, Three New Lilly Deals, and More
Intellia Files First CRISPR‑Based BLA, Testing FDA’s New Post‑Approval Guidance
A One-Time Experimental Treatment Might Control Cholesterol for Life
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
CRISPR Therapeutics' One‑Time Gene Edit Cuts LDL by 49% in Early Trial
CRISPR Gene Edit Cuts LDL by 49% in Early Trial, Offering Durable Cholesterol Solution
One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
STAT+: Eli Lilly Says Verve’s Gene Editor Lowers Cholesterol Levels in Early Study
Verve Therapeutics’ One‑Dose Gene Edit Cuts LDL 62% for Six Months
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Recent Deals
No recent deals for this company.